{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:22:00Z","timestamp":1794561720072,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106622"],"award-info":[{"award-number":["JP20ck0106622"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19EA1008"],"award-info":[{"award-number":["19EA1008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ck0106622h0003"],"award-info":[{"award-number":["22ck0106622h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eclinm.2024.102447","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:24:27Z","timestamp":1706829867000},"page":"102447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-3052","authenticated-orcid":false,"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102447_bib1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.eclinm.2024.102447_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2024.102447_bib3","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102447_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/glioma.glioma_33_18","article-title":"BRAF mutation marks out specific subgroups of glioma","volume":"1","author":"Chan","year":"2018","journal-title":"Glioma"},{"key":"10.1016\/j.eclinm.2024.102447_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2024.102447_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1158\/1535-7163.MCT-15-0643","article-title":"Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm","volume":"15","author":"Turski","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eclinm.2024.102447_bib7","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib8","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib activity in patients with solid tumors and lymphomas harboring BRAF Non-V600 mutations or fusions: results from NCI-MATCH (EAY131)","volume":"26","author":"Johnson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2024.102447_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/onco.13795","article-title":"Efficacy and safety of trametinib in non-V600 BRAF mutant melanoma: a phase II study","volume":"26","author":"Nebhan","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2024.102447_bib10","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2024.102447_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jjco\/hyaa028","article-title":"Regulatory changes after the enforcement of the new clinical trials act in Japan","volume":"50","author":"Nakamura","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrd.2016.68","article-title":"Evolution of frameworks for expediting access to new drugs in Japan","volume":"15","author":"Fujiwara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.eclinm.2024.102447_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1611","article-title":"Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901","volume":"41","author":"Ando","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib17","article-title":"Prospective trial of patient-proposed healthcare services with multiple targeted agent (NCCH1901\/BELIEVE trial): the progress and new challenge for pediatric malignancies","volume":"67","author":"Nakajima","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.eclinm.2024.102447_bib18","article-title":"Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE trial","author":"Ando","year":"2023","journal-title":"Cancer Science"},{"key":"10.1016\/j.eclinm.2024.102447_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10147-023-02439-2","article-title":"Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial","volume":"29","author":"Ishimaru","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)","volume":"26","author":"Naito","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib21","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780121516","article-title":"Applying Bayesian ideas in drug development and clinical trials","volume":"12","author":"Spiegelhalter","year":"1993","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2024.102447_bib22","first-page":"1184","article-title":"Dabrafenib versus dabrafenib\u00a0+ trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.eclinm.2024.102447_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2024.102447_bib24","article-title":"Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - a mini-review","volume":"1865","author":"Lokeswari","year":"2021","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.eclinm.2024.102447_bib25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102447_bib26","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102447_bib28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:38:23Z","timestamp":1781642303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"alternative-id":["S2589537024000269"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102447","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102447"}}